Phenylpiracetam

Russian-developed phenyl-substituted piracetam analog created in 1983 for Soviet cosmonauts — the only racetam on the WADA prohibited list because it is the only one that produces a clear stimulant lift with measurable physical-performance and cold-tolerance benefit. At 100-200 mg AM it gives clean drive + alertness + cognitive throughput + physical edge with no jitters, but tolerance reliably builds in 1-2 weeks of daily use — verdict is STRONG-CANDIDATE-PRN, not daily. Strong fit for Dylan's high-cognitive-load business days and pre-training pulses (2-3×/week max). Cost ~$20-35/mo gray-market via RUPharma / CosmicNootropic; pharma-grade tablets exist (Nanotropil Novo, Aktitropil) so you can avoid powder and CoA gambling.

Phenylpiracetam is racemic 2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide — piracetam with a phenyl group added at the 4-position of the pyrrolidone ring. That single phenyl addition transforms it from a clean cognitive-only racetam into a stimulant-class racetam with multimodal CNS action. The active enantiomer is (R)-phenylpiracetam. Recent work (Zvejniece et al. 2017, MRZ-9547 program at Merz) has clarified the molecular pharmacology that older Russian work was not equipped to characterize:

1. Dopaminergic arm — atypical DAT inhibition (the load-bearing mechanism). (R)-phenylpiracetam is an atypical dopamine transporter (DAT) inhibitor with an IC50 of ~4.82 μM for DAT binding and ~14.5 μM for functional dopamine reuptake inhibition in human recombinant DAT assays. Importantly, it is also a dual DAT/NET reuptake inhibitor — it inhibits norepinephrine transporter (NET) at IC50 ~182 μM (~11-fold lower NET vs. DAT affinity). This DAT inhibition is mechanistically similar to modafinil (also an atypical DAT inhibitor) and explains the stim-like phenomenology that no other racetam produces. The "atypical" classification means it does not produce the abuse profile of cocaine-type DAT inhibitors despite the same target — likely because of different binding kinetics and absence of the conformational changes that drive reinforcement.

2. Receptor density upregulation — indirect dopaminergic + GABA effects. Russian primary research (Firstova et al. 2011, plus earlier Akhapkina lab work) demonstrated that single-dose 100 mg/kg phenotropil in rats increases the density (Bmax) of striatal receptors: D1 +16%, D2 +29%, D3 +62%, benzodiazepine site +25%. Phenylpiracetam itself does not bind D1/D2/D3 — the upregulation is indirect, presumably downstream of DAT inhibition + tonic D-receptor activation. The benzodiazepine-site density increase is the proposed mechanism for the mild anxiolytic component reported by Russian clinicians. Encyclopedia accuracy note: the framing "phenylpiracetam binds D1/D2/D3 receptors" appears in some secondary sources but is incorrect — it binds DAT, not the D-receptors themselves. The receptor density effect is downstream/indirect.

3. Cholinergic arm — α4β2 nicotinic ACh receptor modulation. Phenylpiracetam binds α4β2 nicotinic acetylcholine receptors in cerebral cortex with IC50 ~5.86 μM — a fairly potent direct nAChR effect. This is the AChE-like-effect framing used loosely in the encyclopedia: it is not AChE inhibition (no IC50 against acetylcholinesterase has been reported), but rather direct nAChR modulation at α4β2, the same subtype targeted by varenicline. Net effect functionally resembles cholinergic enhancement — better learning, attention, working memory — and explains the well-known dose-dependent headache that responds to choline supplementation (alpha-GPC or CDP-choline 250-500 mg pre-dose). The Firstova 2011 study also documented that phenotropil decreases the number of cortical NMDA and AChR receptors after a single dose — a homeostatic counter-response to acute receptor activation, with unclear long-term implications.

4. Glutamatergic arm — NMDA receptor modulation (indirect). Like other racetams (notably AMPA-PAM activity at the parent compound piracetam), phenylpiracetam interacts with the glutamate system. The Firstova 2011 work documented decreased NMDA receptor density in scopolamine-treated rats. Other Russian work attributes part of the "neuroprotective" framing to glutamate stabilization in ischemic conditions, but the molecular detail here is thinner than the DAT/nAChR arms.

5. Hypoxia + hypothermia tolerance — the actoprotector arm. This is the cosmonaut-mission mechanism that earned phenylpiracetam its inclusion in the Soyuz emergency medical kit. Russian preclinical work (Bobkov et al. 1983 original characterization, plus follow-ups) documented increased resistance to hypoxic stress, hypothermia, and physical exertion in rats. The "cold tolerance" effect — frequently cited in user reports — is the most distinctive single property of phenylpiracetam and is directly traceable to its development brief at the Institute of Biomedical Problems (Akhapkina lab). Mechanism is presumably multimodal: improved cerebral blood flow under hypoxic conditions + sympathetic activation via DAT/NET inhibition + thermoregulation downstream of DA tone + actoprotector-class membrane stabilization.

6. Cerebral blood flow enhancement. Like piracetam, phenylpiracetam improves regional cerebral blood flow (especially in ischemic regions) — this is the basis for the Russian post-stroke / encephalopathy clinical literature. Mechanism likely overlaps with piracetam's known effects on erythrocyte deformability and platelet aggregation, plus DA-mediated vasomotor tone.

Pharmacokinetics:

• Bioavailability: ~100% oral
• Tmax: ~1 hour (effects often felt within 30 min)
• Half-life: 3-5 hours in humans (2.5-3 hours in rodents)
• Volume of distribution: crosses BBB efficiently
• Metabolism: Phenylpiracetam is not metabolized — excreted unchanged
• Excretion: ~40% in urine, ~60% in bile and sweat (unchanged drug)
• Detection window for WADA testing: detectable in urine for ~1.5 weeks after single dose

The unmetabolized, half-clean-half-sweat excretion profile is unusual and clinically convenient — no CYP interactions to worry about, no hepatic load, predictable kinetics. The 3-5 hour half-life means a single AM dose covers a workday but rarely interferes with sleep if dosed before noon.